Patrick Amstutz
Fortuna: 3 M $ al 30/06/2026
Fortuna: 3 M $ al 30/06/2026
Patrick Amstutz is the founder of Molecular Partners AG, founded in 2004, holding the title of Chief Executive Officer & Director since 2017.
Dr. Amstutz currently holds the positions of Chief Executive Officer & Director at Molecular Partners, Inc. and President at the Swiss Biotech Association since 2022.
Dr. Amstutz completed a doctorate at the University of Zurich and a graduate degree at the Swiss Federal Institute of Technology.
| Empresa | Fecha | Número de acciones | Valoración | Fecha de valoración |
|---|---|---|---|---|
MOLECULAR PARTNERS AG 1,88 % | 31/12/2025 | 759.913 ( 1,88 % ) | 3 M $ | 30/06/2026 |
| Empresas | Cargo | Inicio |
|---|---|---|
| MOLECULAR PARTNERS AG | Fundador | 22/11/2004 |
Swiss Biotech Association
Swiss Biotech Association Miscellaneous Commercial ServicesCommercial Services Operates as an industry association | Presidente | 03/05/2022 |
Molecular Partners, Inc.
Molecular Partners, Inc. Pharmaceuticals: MajorHealth Technology Operates as a clinical-stage biopharmaceutical company | Director Ejecutivo | - |
Activas
Inactivas
Empresas cotizadas
Empresas privadas
Relaciones de 1er grado
Empresas vinculadas al 1er grado
Hombre
Mujer
Administradores
Ejecutivos
| Empresas privadas | 5 |
|---|---|
University of Zurich
University of Zurich Other Consumer ServicesConsumer Services Functions as a College/University | Consumer Services |
Swiss Federal Institute of Technology
Swiss Federal Institute of Technology Other Consumer ServicesConsumer Services Functions as a College/University | Consumer Services |
Molecular Partners AG
Molecular Partners AG BiotechnologyHealth Technology Engages in discovery, development and commercialization of biopharmaceutical products | Health Technology |
Swiss Biotech Association
Swiss Biotech Association Miscellaneous Commercial ServicesCommercial Services Operates as an industry association | Commercial Services |
Molecular Partners, Inc.
Molecular Partners, Inc. Pharmaceuticals: MajorHealth Technology Operates as a clinical-stage biopharmaceutical company | Health Technology |
Selecciona tu edición
Toda la información financiera adaptada al ámbito nacional.